Johnson Chemical Pharmaceutical Works Co., Ltd. AI Stock Analysis
Johnson Chemical Pharmaceutical Works Co., Ltd. (4747) AI Stock Analysis
Johnson Chemical Pharmaceutical Works Co., Ltd.
(TPEx:4747)
The overall score is constrained by significant operational headwinds. The most impactful factor is the poor cash flow generation, with free cash flow nearly evaporating despite a revenue surge, signaling low earnings quality. This is compounded by bearish technicals, with the stock in a clear downtrend below all major moving averages. A strong, low-debt balance sheet and a reasonable valuation provide some defense, but do not fully offset the deteriorating fundamentals and weak market momentum.
Johnson Chemical Pharmaceutical Works Co., Ltd. (4747) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.32B
- Dividend Yield
- 3.66%
- Average Volume (3M)
- 235.37K
- Price to Earnings (P/E)
- -23.4
- Beta (1Y)
- 0.19
- Revenue Growth
- 4.56%
- EPS Growth
- -172.55%
- Country
- TW
- Employees
- 188
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Johnson Chemical Pharmaceutical Works Co., Ltd. Business Overview & Revenue Model
Company Description
Johnson Chemical Pharmaceutical Works Co., Ltd., established in 1959 and headquartered in New Taipei City, Taiwan, is a Taiwanese company that engages in the manufacturing, importing, and distribution of pharmaceutical raw materials, active ingredien...
Johnson Chemical Pharmaceutical Works Co., Ltd. Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is strong with low leverage (D/E 0.15), but this is offset by declining margins, a weak cash conversion ratio (0.19), and a severe 78% drop in free cash flow to just 7.7M, indicating poor earnings quality.
Income Statement
55NeutralBalance Sheet
72PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 577.93M | 569.77M | 611.41M | 606.71M | 494.67M | 411.49M |
| Gross Profit | 227.10M | 228.35M | 247.97M | 244.63M | 204.38M | 171.92M |
| EBITDA | 80.63M | 93.67M | 133.19M | 126.59M | 101.74M | 78.30M |
| Net Income | 89.38M | 53.51M | 84.12M | 79.70M | 64.85M | 49.10M |
Balance Sheet | ||||||
| Total Assets | 2.56B | 2.09B | 1.97B | 1.99B | 1.04B | 1.03B |
| Cash, Cash Equivalents and Short-Term Investments | 261.73M | 1.15B | 1.07B | 1.09B | 168.47M | 202.23M |
| Total Debt | 645.00M | 260.95M | 150.22M | 160.83M | 60.00M | 80.00M |
| Total Liabilities | 820.26M | 384.37M | 261.36M | 320.99M | 167.56M | 178.91M |
| Stockholders Equity | 1.74B | 1.71B | 1.70B | 1.67B | 871.66M | 848.24M |
Cash Flow | ||||||
| Free Cash Flow | -40.87M | 7.66M | 49.68M | 103.83M | 29.98M | 15.06M |
| Operating Cash Flow | 24.29M | 71.71M | 62.88M | 136.95M | 89.69M | 52.35M |
| Investing Cash Flow | -1.30B | -153.76M | -12.96M | -33.28M | -59.92M | -38.15M |
| Financing Cash Flow | 444.87M | 61.53M | -67.47M | 815.47M | -63.53M | -107.64M |
Johnson Chemical Pharmaceutical Works Co., Ltd. Peers Comparison
Overall Rating
TW:827969Neutral
TW:414860Neutral
TW:474751Neutral
TW:410847Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | TWD 2.19B | 10.63 | ― | 6.21% | -3.92% | -29.93% | |
| 60Neutral | TWD 1.98B | 10.66 | ― | 3.40% | 21.39% | 54.64% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | TWD 1.44B | -23.41 | ― | 3.66% | 4.56% | -172.55% | |
| 47Neutral | TWD 2.07B | -47.97 | ― | ― | 1.10% | 54.83% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4747 | Johnson Chemical Pharmaceutical Works Co., Ltd. | 14.35 | -16.88 | -54.05% | |
| TW:4108 | Phytohealth Corporation | 10.30 | -4.00 | -27.97% | |
| TW:4148 | All Cosmos Bio-Tech Holding Corp. | 29.40 | -11.51 | -28.13% | |
| TW:6659 | Timing Pharmaceutical Co. Ltd. | 19.35 | -20.61 | -51.57% | |
| TW:7888 | Libo Pharma Corp. | 24.30 | -20.85 | -46.18% | |
| TW:8279 | Syngen Biotech Co., Ltd. | 80.50 | -42.66 | -34.64% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
